Literature DB >> 28861210

Pharmacogenetics and precision medicine: Is inflammation a covert threat to effective genotype-based therapy?

Rashmi R Shah1.   

Abstract

Year:  2017        PMID： 28861210      PMCID： PMC5557163          DOI： 10.1177/2042098617712657

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  42 in total

1.  Inflammation: planning for a source of pharmacokinetic/pharmacodynamic variability in translational studies.

Authors:  V D Schmith; J F Foss
Journal:  Clin Pharmacol Ther       Date:  2010-02-10       Impact factor: 6.875

2.  Therapeutic protein-drug interactions and implications for drug development.

Authors:  S-M Huang; H Zhao; J-I Lee; K Reynolds; L Zhang; R Temple; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2010-03-03       Impact factor: 6.875

3.  Plasma levels of TNF-alpha and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure.

Authors:  Reginald F Frye; Virginia M Schneider; Carole S Frye; Arthur M Feldman
Journal:  J Card Fail       Date:  2002-10       Impact factor: 5.712

4.  Drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis.

Authors:  Noriko Daneshtalab; Richard Z Lewanczuk; Anthony S Russell; Fakhreddin Jamali
Journal:  J Clin Pharmacol       Date:  2006-11       Impact factor: 3.126

5.  Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis.

Authors:  C Schmitt; B Kuhn; X Zhang; A J Kivitz; S Grange
Journal:  Clin Pharmacol Ther       Date:  2011-03-23       Impact factor: 6.875

6.  Association of inflammatory factors with occurrence and recurrence of atrial fibrillation: a meta-analysis.

Authors:  Na Wu; Bin Xu; Ying Xiang; Long Wu; Yao Zhang; Xiangyu Ma; Shifei Tong; Maoqing Shu; Zhiyuan Song; Yafei Li; Li Zhong
Journal:  Int J Cardiol       Date:  2013-09-08       Impact factor: 4.164

7.  Relation of elevated C-reactive protein and interleukin-6 levels to left atrial size and duration of episodes in patients with atrial fibrillation.

Authors:  Stavroula N Psychari; Thomas S Apostolou; Loukas Sinos; Eftihia Hamodraka; George Liakos; Dimitrios Th Kremastinos
Journal:  Am J Cardiol       Date:  2005-03-15       Impact factor: 2.778

8.  Cytochrome p-450 polymorphisms and response to clopidogrel.

Authors:  Jessica L Mega; Sandra L Close; Stephen D Wiviott; Lei Shen; Richard D Hockett; John T Brandt; Joseph R Walker; Elliott M Antman; William Macias; Eugene Braunwald; Marc S Sabatine
Journal:  N Engl J Med       Date:  2008-12-22       Impact factor: 91.245

9.  Prognostic impact of hs-CRP and IL-6 in patients with persistent atrial fibrillation treated with electrical cardioversion.

Authors:  Kristoffer Mads Aaris Henningsen; Susette Krohn Therkelsen; Helle Bruunsgaard; Karen S Krabbe; Bente Klarlund Pedersen; Jesper Hastrup Svendsen
Journal:  Scand J Clin Lab Invest       Date:  2009       Impact factor: 1.713

10.  Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications.

Authors:  Y Zhang; L Zhang; S Abraham; S Apparaju; T-C Wu; J M Strong; S Xiao; A J Atkinson; K E Thummel; J S Leeder; C Lee; G J Burckart; L J Lesko; S-M Huang
Journal:  Clin Pharmacol Ther       Date:  2008-11-19       Impact factor: 6.875
View more
  9 in total

Review 1.  Precision medicine: does ethnicity information complement genotype-based prescribing decisions?

Authors:  Rashmi R Shah; Andrea Gaedigk
Journal:  Ther Adv Drug Saf       Date:  2017-12-01

Review 2.  Ten Years' Experience with the CYP2D6 Activity Score: A Perspective on Future Investigations to Improve Clinical Predictions for Precision Therapeutics.

Authors:  Andrea Gaedigk; Jean C Dinh; Hyunyoung Jeong; Bhagwat Prasad; J Steven Leeder
Journal:  J Pers Med       Date:  2018-04-17

3.  No Effect of Dose Adjustment to the CYP2D6 Genotype in Patients With Severe Mental Illness.

Authors:  Anne B Koopmans; David J Vinkers; Igmar T Poulina; Petra J A Gelan; Ron H N van Schaik; Hans W Hoek; Peter N van Harten
Journal:  Front Psychiatry       Date:  2018-08-07       Impact factor: 4.157

4.  Dasatinib-induced nephrotic syndrome: a case of phenoconversion.

Authors:  Inga Mandac Rogulj; Vid Matišić; Borna Arsov; Luka Boban; Alen Juginović; Vilim Molnar; Dragan Primorac
Journal:  Croat Med J       Date:  2019-06-13       Impact factor: 1.351

5.  Different Pharmacokinetics of Tramadol, O-Demethyltramadol and N-Demethyltramadol in Postoperative Surgical Patients From Those Observed in Medical Patients.

Authors:  Nenad Neskovic; Dario Mandic; Saska Marczi; Sonja Skiljic; Gordana Kristek; Hrvoje Vinkovic; Boris Mraovic; Zeljko Debeljak; Slavica Kvolik
Journal:  Front Pharmacol       Date:  2021-04-15       Impact factor: 5.810

6.  CYP2B6 allelic variants and non-genetic factors influence CYP2B6 enzyme function.

Authors:  Katalin Mangó; Ádám Ferenc Kiss; Ferenc Fekete; Réka Erdős; Katalin Monostory
Journal:  Sci Rep       Date:  2022-02-22       Impact factor: 4.379

7.  Drug genetic associations with COVID-19 manifestations: a data mining and network biology approach.

Authors:  Theodosia Charitou; Panagiota I Kontou; Ioannis A Tamposis; Georgios A Pavlopoulos; Georgia G Braliou; Pantelis G Bagos
Journal:  Pharmacogenomics J       Date:  2022-09-28       Impact factor: 3.245

Review 8.  Pharmacogenetics Approach for the Improvement of COVID-19 Treatment.

Authors:  Ingrid Fricke-Galindo; Ramcés Falfán-Valencia
Journal:  Viruses       Date:  2021-03-05       Impact factor: 5.048

Review 9.  Meta-analysis of probability estimates of worldwide variation of CYP2D6 and CYP2C19.

Authors:  Anne B Koopmans; Mario H Braakman; David J Vinkers; Hans W Hoek; Peter N van Harten
Journal:  Transl Psychiatry       Date:  2021-02-24       Impact factor: 6.222
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.